QPPV.COM KNOWLEDGE ASSESSMENT

How the EU Medicines Regulatory System Works

Test your understanding of the concepts covered by How the EU Medicines Regulatory System Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should a professional not identify a referral solely by naming the committee that assessed it?

Committees cannot assess regulatory evidence The same committee may be involved in procedures with different legal bases, triggers and legal consequences Committee names are not used in EU regulatory documents Only national authorities can initiate referrals

Question 2 of 10 What is the most precise description of the centralised marketing-authorisation sequence for a human medicine?

National competent authority decision followed by EMA confirmation EMA and CHMP scientific assessment followed by a European Commission decision PRAC assessment followed directly by a legally binding Union authorisation CMDh assessment followed by simultaneous national authorisations

Question 3 of 10 Which statement best distinguishes a national authorisation from a centralised authorisation?

A national authorisation is outside the common EU scientific and legal framework A national authorisation initially applies within an individual Member State, while a centralised authorisation is a Union authorisation A national authorisation is subject only to safety requirements, not quality and efficacy requirements A centralised authorisation is granted by the RMS on behalf of all Member States

Question 4 of 10 Which statement best describes the QPPV's role in relation to the wider EU regulatory system?

The QPPV is the legal decision-maker for every EU medicines procedure The QPPV needs oversight of the pharmacovigilance system and relevant safety information but does not decide every regulatory issue The QPPV is responsible only for manufacturing quality The QPPV replaces PRAC and national competent authorities

Question 5 of 10 Which sequence most appropriately represents the distinction between scientific assessment and legal decision-making?

Legal decision, evidence generation, scientific assessment, implementation Evidence, scientific assessment, committee opinion or recommendation, legally operative decision where required, implementation Implementation, committee opinion, national authorisation, evidence generation EMA webpage, applicant communication, automatic legal effect

Question 6 of 10 Why is the statement 'EMA approved the medicine' imprecise in formal regulatory writing?

EMA has no role in centralised applications CHMP, rather than EMA, is the only body with legal authority to authorise medicines EMA coordinates scientific assessment, while the European Commission adopts the legally binding centralised decision National authorities always issue the final centralised authorisation

Question 7 of 10 What is the most appropriate interpretation of a PRAC recommendation?

It is automatically identical to the final legally binding decision in every procedure It is a scientific or regulatory recommendation whose legal effect depends on the applicable procedure and subsequent instrument It always replaces a European Commission decision It has no relevance to product information or risk management

Question 8 of 10 A company is assessing which EU procedure applies to a new regulatory issue. What should it establish first?

Which agency website contains the most recent document Which committee has the most prominent role in the issue The product status, legal basis and procedural trigger Whether the issue has received media attention

Question 9 of 10 Why is a marketing authorisation best understood as a regulatory baseline rather than a permanent declaration of universal safety and efficacy?

It establishes authorised conditions of use that may be modified when evidence changes It has no legal effect after launch It applies only to manufacturing and not to clinical use It guarantees that all patients will experience a positive outcome

Question 10 of 10 What is the most useful practical framework for classifying a new EU medicines regulatory question?

Identify the product, authorisation status, legal basis, responsible body, evidence and operative outcome Start with the most familiar committee and infer the remaining details Focus only on whether the issue is safety-related Select the shortest available procedure before reviewing the evidence

How the EU Medicines Regulatory System Works

Cookie Settings